NeoMero
European multicenter network to evaluate pharmacokinetics, safety and efficacy of Meropenem in neonatal sepsis and meningitis
NeoMero1: An open label, randomised, multicenter, comparator-controlled study to evaluate the PK, efficacy and safety of meropenem as compared with standard antibiotic therapy in neonates and infants aged < 3 months treated in neonatal intensive care units (NICU) for late onset sepsis (LOS) defined as sepsis appearing after 72 hrs from birth;
NeoMero2: An open label, multicenter, observational study to evaluate the PK and safety of meropenem in neonates and infants aged < 3 months with bacterial meningitis admitted to NICUs.
Link
EUDRA-CT
2011-001515-31
Funding
European Commission, under the FP7 programme
Partners
- University of Tartu, Estonia;
- INSERM SC10-US19, France;
- Azienda Ospedaliera-University of Padua, Padua-Italy;
- Bambino Gesù Children’s Hospital, IRCCS, Rome Italy;
- University Department of Paediatrics, Italy;
- Neonatoloji Kliniği, Turkey;
- Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Italy;
- Tallinn Children’s Hospital, Estonia;
- St George's University of London, UK;
- Aristotle University School of Health Sciences, Hippokration Hospital, Greece;
- Tartu University Hospital, Estonia;
- Aristotle University School of Health Sciences, Papageorgiou Hospital, Greece;
- Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Italy;
- Hospital Universitario Infantil LA PAZ- H. Carlos III; Vilnius University,Lithuania;
- University of Aberdeen, UK;
- University of Padova, Italy
People involved with the project
